CXCL10 and multiple sclerosis: Subcutaneous injections of IFN-β in multiple sclerosis patients were shown to initiate an inflammatory skin reaction characterized by enhanced CCL2, CCL5 and CXCL10 in keratinocytes and infiltrating leucocytes [15], actually the same chemokines strongly up-regulated in response to EGFR inhibition in human and mouse keratinocytes, in vitro and in vivo [8–11, 14].